Supreme Court Clarifies Liability for Generic Drug Manufacturers Using 'Skinny Labels'

The Supreme Court issued a unanimous decision in Hikma v. Amarin, rejecting multiple Federal Circuit rulings. The ruling clarifies whether and when a generic manufacturer can be held liable for induced infringement when marketing drugs with a 'skinny label,' which carves out patented uses and includes only unpatented indications. This decision has implications for generic drug labeling strategies and pharmaceutical patent litigation.